¹Ì±¹ÀÇ Æ¯¼ö Á¦³×¸¯ ÀǾàǰ(ÁÖ»çÁ¦) ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® º¸°í¼ : À¯Çüº°, ¿ëµµº°, À¯Åë ä³Îº°, ºÎ¹®º° ¿¹Ãø(2023-2030³â)
U.S. Specialty Injectable Generics Market Size, Share & Trends Analysis Report By Type (Drugs, Biologics), By Application (Oncology, CNS, Cardiovascular), By Distribution Channel (Hospitals, Retail Pharmacy), And Segment Forecasts, 2023 - 2030
»óǰÄÚµå
:
1362918
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2023³â 09¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 100 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¹Ì±¹ÀÇ Æ¯¼ö Á¦³×¸¯ ÀǾàǰ(ÁÖ»çÁ¦) ½ÃÀå ¼ºÀå ¹× µ¿Çâ :
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ¹Ì±¹ÀÇ Æ¯¼ö Á¦³×¸¯ ÀǾàǰ(ÁÖ»çÁ¦) ½ÃÀåÀº 2023³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 8.33% ¼ºÀåÇÏ¿© 2030³â 3,616¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÈ´Ù°í ÇÕ´Ï´Ù. ¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¹Ì±¹ ³» ÁÖ¿ä Á¦¾à»çµéÀÇ ³ôÀº Á¸Àç°¨°ú ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡°¡ ÁÖ¿ä ¼ºÀå µ¿ÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, Ư¼ö Á¦³×¸¯ ÀǾàǰ(ÁÖ»çÁ¦)ÀÇ FDA ½ÂÀÎ Áõ°¡, »õ·Î¿î R&D Ȱµ¿ ¹× È®¸³µÈ ÀÇ·á ÀÎÇÁ¶ó°¡ ¹Ì±¹ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
¹Ì±¹¿¡¼´Â ¾Ï Áø´Ü ¹× Ä¡·á ¼ö¿ä Áõ°¡·Î ÀÎÇØ Ư¼ö Á¦³×¸¯ ÀǾàǰ(ÁÖ»çÁ¦)¿¡ ´ëÇÑ ¾öû³ ¼ö¿ä°¡ ¹ß»ýÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¾ÏÇùȸ¿¡ µû¸£¸é 2022³â ¹Ì±¹¿¡¼ 1,900¸¸ ¸íÀÇ ¾Ï ȯÀÚ°¡ »õ·Î Áø´ÜµÇ°í 609,360¸íÀÌ »ç¸ÁÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ ±â¾÷µéÀº ¾Ï ȯÀÚµéÀ» À§ÇÑ Çõ½ÅÀûÀ̰í È¿°úÀûÀÎ Ä¡·á¹ýÀ» °³¹ßÇÏ´Â µ¥ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 11¿ù Amneal Pharmaceuticals, Inc.´Â ¹Ì±¹ FDA·ÎºÎÅÍ ·ùÇÁ·Î¸®µå ¾Æ¼¼Å×ÀÌÆ®ÀÇ ½Å¾à ½ÂÀÎ(abbreviated new drug application)À» ȹµæÇß½À´Ï´Ù. ÀÌ ÁÖ»çÁ¦´Â ÁøÇ༺ Àü¸³¼±¾Ï Ä¡·á¿¡ »ç¿ëµË´Ï´Ù.
¶ÇÇÑ, ÀǾàǰÀº ¼ÒºñÀÚ¿¡°Ô ´Ù¾çÇÑ Ä¡·á¹ýÀ» Á¦°øÇϰí ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϱ⠶§¹®¿¡ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Ư¼ö Á¦³×¸¯ ÀǾàǰ(ÁÖ»çÁ¦)ÀÇ ±â¼ú Çõ½ÅÀÌ °è¼ÓµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ¹Ì±¹¿¡ ÀÌÀÍÀ» °¡Á®´ÙÁÖ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 6¿ù Dr. Reddy's Laboratories Ltd.´Â Eton Pharmaceuticals, Inc.ÀÇ ºê·£µå ¹× Á¦³×¸¯ ÁÖ»çÁ¦ Æ÷Æ®Æú¸®¿À¸¦ ÀμöÇß½À´Ï´Ù. À̹ø Àμö´Â Dr. Reddy's°¡ ȯÀڵ鿡°Ô Àú·ÅÇÑ ÀǾàǰÀ» È®´ë ¹× °¡¼ÓÈÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀÔ´Ï´Ù. À̹ø Àμö·Î Dr.Reddy'sÀÇ ¹Ì±¹ ³» ±â°üÅõÀÚÀÚ ºñÁî´Ï½º¿¡ °æÀïÀÌ ÀûÀº ÁÖ»çÁ¦¸¦ Ãß°¡ÇÏ°Ô µË´Ï´Ù.
¸¶Âù°¡Áö·Î Äڷγª19ÀÇ ´ëÀ¯ÇàÀº Ư¼ö Á¦³×¸¯ ÀǾàǰ(ÁÖ»çÁ¦) ½ÃÀå¿¡µµ ¾î´À Á¤µµ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ÆÒµ¥¹Í ±â°£ µ¿¾È Ư¼ö ÁÖ»çÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ ºü¸£°Ô Áõ°¡Çß½À´Ï´Ù. ±×·¯³ª »ý»ê·®°ú Á¦Ç° ºÎÁ·, º´¿ø°ú ¼Ò¸Å ¾à±¹°ø±Þ¸Á È¥¶õÀ¸·Î ÀÎÇØ °ø±Þ¸Á¿¡ ¾î´À Á¤µµ Àå¾Ö°¡ ¹ß»ýÇß½À´Ï´Ù. ±â¾÷ÀÌ Á÷¸éÇÑ Áß¿äÇÑ ¹®Á¦ Áß Çϳª´Â »ý»ê ¼ö¿ä¿Í ÃÖÁ¾ »ç¿ëÀÚ¿¡ ´ëÇÑ Á¦Ç° °ø±ÞÀ̾ú½À´Ï´Ù. ±×·¯³ª ÆÒµ¥¹Í ÀÌÈÄ ½ÃÀåÀº »ý»ê°ú °ø±Þ¸Á È®´ë·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ, ÁÖ¿ä ÁøÃâ±â¾÷µéÀº ÆÄÆ®³Ê½Ê, °è¾à, M&A, Á¦ÈÞ, Ãâ½Ã µîÀÇ Àü·«À» ÅëÇØ ¼¼°è ¹ßÀÚÃë¿Í Æ÷Æ®Æú¸®¿À¸¦ È®´ëÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 1¿ù ¹Ì±¹ ±Û·»¸¶Å©´Â ºÎ¸ÞŸ´Ïµå ÁÖ»çÁ¦ USP, 1mg/4mL 1ȸ¿ë ¹ÙÀ̾Ë, 2.5mg/10ȸ¿ë ¹ÙÀ̾ËÀ» Ãâ½ÃÇÏ¿´½À´Ï´Ù. ÀÌ´Â ¹Ù¸®´Ù½º ÆÄ¸¶½´Æ¼Äýº(Varidas Pharmaceuticals)ÀÇ ºÎ¸ß½º1 ÁÖ»çÁ¦ 0.25mg/mLÀÇ Á¦³×¸¯ ÀǾàǰÀÔ´Ï´Ù. ¸¶Âù°¡Áö·Î 2022³â 10¿ù, ¾ÆÄÜ ¿ÀÆÛ·¹ÀÌÆÃ ÄÄÆÛ´Ï(Akorn Operating Company LLC)´Â 2022³â ¹Ì±¹ »ý½ÄÀÇÇÐ ÇÐȸ(͏®Æ÷´Ï¾Æ)¿¡¼ ¼¼Æ®·Î·¼¸¯½º ¾Æ¼¼Å×ÀÌÆ® 0.25mg ÁÖ»çÁ¦(¼¼Æ®·Î·¼¸¯½º)ÀÇ Á¦³×¸¯À» Ãâ½ÃÇÏ¿´½À´Ï´Ù.
¹Ì±¹ÀÇ Æ¯¼ö Á¦³×¸¯ ÀǾàǰ(ÁÖ»çÁ¦) ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- À¯Çüº°·Î´Â »ý¹°ÇÐÀû Á¦Á¦ ºÐ¾ß°¡ 2022³â °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¸¸¼º Áúȯ Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ¾î ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- 2022³â ¹Ì±¹ ½ÃÀå¿¡¼´Â ¾Ï ºÐ¾ß°¡ 48.9%ÀÇ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀÇ ¹è°æ¿¡´Â ¾Ï ȯÀÚÀÇ ºÎ´ãÀÌ Áõ°¡Çϰí À¯¹æ¾Ï, Æó¾Ï µîÀÇ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô±â ¶§¹®ÀÎ °ÍÀ¸·Î ºÐ¼®µË´Ï´Ù.
- À¯Åë ä³Îº°·Î´Â º´¿ø ¾à±¹ÀÇ Á¸Àç¿Í ÁßÁõ ȯÀÚÀÇ ÁÖ»çÁ¦ ¼ö¿ä Áõ°¡·Î ÀÎÇØ º´¿ø ¾à±¹ ºÎ¹®ÀÌ 2022³â ¹Ì±¹ ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
- ÀÌ ºÐ¾ß¿¡¼ »ç¾÷À» Àü°³ÇÏ´Â ÁÖ¿ä ±â¾÷µéÀº Á¸Àç°¨À» À¯ÁöÇϱâ À§ÇØ ²÷ÀÓ¾øÀÌ Á¦Ç° Ãâ½Ã¿Í Áö¸®Àû È®Àå¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- ½ÃÀå ¿ªÇÐ
- SWOT ºÐ¼®(¿äÀκ°)
- ¾÷°è ºÐ¼® - PorterÀÇ Five Forces ºÐ¼®
- ¼ÒºñÀÚ Çൿ ºÐ¼®
- ´ë»ó Áúȯ Áý´Ü
- ±ÔÁ¦ ½Ã³ª¸®¿À
- »óȯ ½Ã³ª¸®¿À
- ¹ÌÃæÁ· ¿ä±¸¿Í ±âȸ ºÐ¼®
- KOL ÀÀ´ä
Á¦4Àå À¯Çü ºñÁî´Ï½º ºÐ¼®
- ¹Ì±¹ÀÇ Æ¯¼ö Á¦³×¸¯ ÀǾàǰ(ÁÖ»çÁ¦) ½ÃÀå : À¯Çü º¯µ¿ ºÐ¼®
- ÀǾàǰ
- »ý¹°Á¦Á¦
Á¦5Àå ¿ëµµ ºñÁî´Ï½º ºÐ¼®
- ¹Ì±¹ÀÇ Æ¯¼ö Á¦³×¸¯ ÀǾàǰ(ÁÖ»çÁ¦) ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®
- Á¾¾ç
- ½ÉÀåÇ÷°ü
- ÁßÃ߽Űæ°è
- °¨¿°Áõ
- ÀÚ°¡¸é¿ªÁúȯ
- ±âŸ
Á¦6Àå À¯Åë ä³Î ºñÁî´Ï½º ºÐ¼®
- ¹Ì±¹ÀÇ Æ¯¼ö Á¦³×¸¯ ÀǾàǰ(ÁÖ»çÁ¦) ½ÃÀå : À¯Åë ä³Î º¯µ¿ ºÐ¼®
- º´¿ø
- ¼Ò¸Å ¾à±¹
- ±âŸ
Á¦7Àå °æÀï ±¸µµ
- ±â¾÷ ºÐ·ù
- Àü·« ¸ÅÇÎ
- ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â
- ±â¾÷ °³¿ä/¸®½ºÆ® Ç¥
LSH
¿µ¹® ¸ñÂ÷
U.S. Specialty Injectable Generics Market Growth & Trends:
The U.S. specialty injectable generics market is expected to reach USD 36.16 million by 2030, expanding at a CAGR of 8.33% from 2023 to 2030, according to a new report by Grand View Research, Inc.. High presence of key pharmaceutical players in the U.S. and the rising prevalence of chronic diseases are among the key drivers for the growth. Furthermore, the growing number of FDA approvals for specialty injectable generics, emerging research & development activities, and well-established healthcare infrastructure contribute to U.S. space growth.
In the U.S., the increasing cancer diagnosis and treatment demand has created immense demand for specialty injectable generics. According to the American Cancer Society, in 2022, it is expected that 1.9 million new oncology cases are anticipated to diagnose and 609,360 cancer deaths in the U.S. This factor has led companies to increase their focus on the development of innovative and effective treatments for oncology cases. For instance, in November 2022, Amneal Pharmaceuticals, Inc. received abbreviated new drug application approval from the U.S. FDA for leuprolide acetate. The injection is used for advanced prostatic cancer treatment.
Furthermore, pharmaceutical drug products have become increasingly important as they provide consumers with an array of treatments and life expectancy-enhancing patient lives. Thereby, continued specialty injectable generics innovation has benefited the U.S. space. For instance, in June 2022, Dr. Reddy's Laboratories Ltd. acquired branded & generic injectable products portfolio from Eton Pharmaceuticals, Inc. The acquisition will support Dr. Reddy's company to expand & accelerate affordable medications for patients. The acquisition will add Dr. Reddy's U.S. institutional business with limited competition injectable products.
Likewise, the COVID-19 pandemic has moderately impacted the specialty injectable generics market. During the pandemic, there was a rapid demand for specialty injections. However, shortage of production and products, and supply chain disruptions in hospitals, retail pharmacy had hampered the supply chain to some extent. One of the key issues faced by companies was production demand and delivery of products to end users. However, post-pandemic the market has witnessed rapid growth with increased production and supply chain.
Furthermore, the key participants are engaged in strategies such as partnerships, agreements, mergers & acquisitions, collaborations, and launches, among others, to expand their global footprints and portfolios. For instance, in January 2023, Glenmark Pharmaceuticals Inc., USA launched Bumetanide Injection USP, 1 mg/4 mL Single-Dose Vials & 2.5 mg/10 Multi-Dose Vials which is Validus Pharmaceuticals, Inc's generic version of Bumex1 Injection, 0.25 mg/mL. Similarly, in October 2022, Akorn Operating Company LLC launched the generic Cetrorelix Acetate for Injection 0.25 mg (Cetrorelix) at the 2022 American Society for Reproductive Medicine Conference, California.
U.S. Specialty Injectable Generics Market Report Highlights:
- Based on type, the Biologics segment held the largest revenue share in 2022 and is anticipated to grow at the fastest growth rate over the forecast period owing to the wide adoption of the biologics in the treatment of chronic diseases
- The oncology segment dominated the U.S. market with a revenue share of 48.9% in 2022. The growth is attributed to the growing burden of cancer cases and strong demand for breast and lung cancer therapies, among other types.
- On the basis of distribution channels, the hospital pharmacy segment dominated the U.S. market in 2022 due to the presence of hospital pharmacies and increased injectable demand among critical patients.
- Key players operating in the space are constantly focusing on product launches and geographical expansion to maintain their presence.
- A few of the key players include Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Baxter International, Novartis AG, Fresenius SE & Co. KGaA, Par Pharmaceutical, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories, Sagent Pharmaceuticals, Inc., Mylan N.V.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.2.1. Segment 1
- 1.2.2. Segment 2
- 1.2.3. Segment 3
- 1.3. Research Methodology
- 1.3.1. Information Analysis
- 1.3.2. Market Formulation & Data Visualization
- 1.3.3. Data Validation & Publishing
- 1.4. Research Assumptions
- 1.5. Information Procurement
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Model
- 1.9. Global Market: CAGR Calculation
- 1.10. Objective
- 1.10.1. Objective 1
- 1.10.2. Objective 2
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Emerging chronic diseases patients
- 3.2.1.2. Increasing number of new FDA injectable generics drugs approvals
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High cost of injectable
- 3.3. SWOT Analysis, by Factor
- 3.4. Industry Analysis- Porter's
- 3.5. Consumer Behavior Analysis
- 3.6. Target Disease Population
- 3.7. Regulatory Scenario
- 3.8. Reimbursement Scenario
- 3.9. Unmet Needs and Opportunity Analysis
- 3.10. KOL Responses
Chapter 4. Type Business Analysis
- 4.1. U.S. Specialty Injectable Generics Market: Type Movement Analysis
- 4.2. Drugs
- 4.2.1. Drugs Market, 2018 - 2030 (USD Million)
- 4.3. Biologics
- 4.3.1. Biologics Market, 2018 - 2030 (USD Million)
Chapter 5. Application Business Analysis
- 5.1. U.S. Specialty Injectable Generics Market: Application Movement Analysis
- 5.2. Oncology
- 5.2.1. Oncology Market, 2018 - 2030 (USD Million)
- 5.3. Cardiovascular
- 5.3.1. Cardiovascular Market, 2018 - 2030 (USD Million)
- 5.4. CNS
- 5.4.1. CNS Market, 2018 - 2030 (USD Million)
- 5.5. Infectious Diseases
- 5.5.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
- 5.6. Autoimmune Disorders
- 5.6.1. Autoimmune Disorders Market, 2018 - 2030 (USD Million)
- 5.7. Others
- 5.7.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Distribution Channel Business Analysis
- 6.1. U.S. Specialty Injectable Generics Market: Distribution Channel Movement Analysis
- 6.2. Hospital
- 6.2.1. Hospital Market, 2018 - 2030 (USD Million)
- 6.3. Retail Pharmacy
- 6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
- 6.4. Others
- 6.4.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Company Categorization
- 7.2. Strategy Mapping
- 7.3. Company Market Share Analysis, 2022
- 7.4. Company Profiles/Listing
- 7.4.1. Pfizer, Inc.
- 7.4.1.1. Overview
- 7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.1.3. Product Benchmarking
- 7.4.1.4. Strategic Initiatives
- 7.4.2. Teva Pharmaceutical Industries Ltd.
- 7.4.2.1. Overview
- 7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.2.3. Product Benchmarking
- 7.4.2.4. Strategic Initiatives
- 7.4.3. Baxter International
- 7.4.3.1. Overview
- 7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.3.3. Product Benchmarking
- 7.4.3.4. Strategic Initiatives
- 7.4.4. Novartis AG
- 7.4.4.1. Overview
- 7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.4.3. Product Benchmarking
- 7.4.4.4. Strategic Initiatives
- 7.4.5. Fresenius SE & Co. KGaA
- 7.4.5.1. Overview
- 7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.5.3. Product Benchmarking
- 7.4.5.4. Strategic Initiatives
- 7.4.6. Par Pharmaceutical
- 7.4.6.1. Overview
- 7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.6.3. Product Benchmarking
- 7.4.6.4. Strategic Initiatives
- 7.4.7. Hikma Pharmaceuticals PLC
- 7.4.7.1. Overview
- 7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.7.3. Product Benchmarking
- 7.4.7.4. Strategic Initiatives
- 7.4.8. Dr. Reddy's Laboratories
- 7.4.8.1. Overview
- 7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.8.3. Product Benchmarking
- 7.4.8.4. Strategic Initiatives
- 7.4.9. Sagent Pharmaceuticals, Inc.
- 7.4.9.1. Overview
- 7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.9.3. Product Benchmarking
- 7.4.9.4. Strategic Initiatives
- 7.4.10. Mylan N.V.
- 7.4.10.1. Overview
- 7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.10.3. Product Benchmarking
- 7.4.10.4. Strategic Initiatives
°ü·ÃÀÚ·á